Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors

Annals of Pharmacotherapy

Volumn 39, Issue 4, 2005, Pages 603-609

  Duong, Michel ^a,b   Buisson, Marielle ^b   Peytavin, Gilles ^c   Kohli, Evelyne ^b   Piroth, Lionel ^b   Martha, Benoit ^b   Grappin, Michèle ^b   Chavanet, Pascal ^b   Portier, Henri ^b  

^a HÔPITAL DU BOCAGE   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c Bichat University   (France)

Author keywords

Nevirapine; Plasma concentration; Treatment failure; Virologic resistance

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CHOICE; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIREMIA;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 15444366999     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E563     Document Type: Article

References (23)

1. Pallela FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV- 1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-8.
3. Petit JM, Duong M, Duvillard L, Piroth L, Grappin M, Verges B, et al. HIV-1 protease inhibitors induce an increase of triglyceride levels in HIV-infected men without modification of insulin sensitivity: a longitudinal study. Horm Metab Res 2000;32:367-72.
4. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. Substitution of nevirapine, efavirenz and abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003;349:1036-46.
5. Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz inpatients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-10.
6. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomised, controlled study. J Acquir Immune Defic Syndr 2001;27:229-36.
7. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12.
8. Masquelier B, Neau D, Chêne G, Larbère J, Birac V, Ragnaud JM, et al. Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2001;28:309-14.
9. Murphy RL. Defining the toxicity profile of nevirapine and other antiretroviral drugs. J Acquir Immune Defic Syndr 2003;34(suppl 1):S15-20.
10. Rolf P, Van Heeswijk O, Hoetelmans R. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1998;713:395-9.
11. Veldkamp A, Weverling H, Lange J, Montaner JS, Reiss P, Cooper DA, et al. High exposure to nevirapine in plasma is associated with an improved response in HIV-1 infected individuals. AIDS 2001;18:1089-95.
12. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002;16:290-1.
13. Wainberg MA. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2003;34(suppl 1):S2-7.
14. Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, Piroth L, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002;16:21-9.
15. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
16. Gil P, de Gorgolas M, Estrada V, Arranz A, Rivas P, Yera C, et al. Long-term efficacy and safety of protease inhibitors switching to nevirapine in HIV-infected patients with undetectable viral load: 3-year results. Clin Infect Dis 2004;39:1024-9.
17. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
18. Halvir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with HIV infection. J Infect Dis 1995;171:537-45.
19. de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003;42:599-605.
20. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999;27:1488-95.
21. Dieleman JP, Sturkenboom MCJM, Wit FW, Jambroes M, Mulder J-W, ten Veen JH, et al. Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression. J Infect Dis 2002;185:1261-8.
22. Chaix ML, Descamps D, Mouajijah S, Deveau C, André P, Cottalorda J, et al. French national sentinel survey of antiretroviral resistance in patients with HIV-1 primary infection and in antiretroviral-naïve chronically infected patients in 2001-2002. Antiviral Ther 2003(abstract);8: S137.
23. Gonzalez de Requena D, Nunez M, Gallego O, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure? HIV Clin Trials 2002;3:463-7.